Annual Accounts Receivable
$9.09 B
+$2.19 B+31.82%
31 December 2023
Summary:
Eli Lilly and Company annual accounts receivable is currently $9.09 billion, with the most recent change of +$2.19 billion (+31.82%) on 31 December 2023. During the last 3 years, it has risen by +$3.22 billion (+54.72%). LLY annual accounts receivable is now at all-time high.LLY Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$10.29 B
-$733.10 M-6.65%
30 September 2024
Summary:
Eli Lilly and Company quarterly accounts receivable is currently $10.29 billion, with the most recent change of -$733.10 million (-6.65%) on 30 September 2024. Over the past year, it has increased by +$2.13 billion (+26.05%). LLY quarterly accounts receivable is now -6.65% below its all-time high of $11.03 billion, reached on 30 June 2024.LLY Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LLY Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +31.8% | +26.1% |
| 3 y3 years | +54.7% | +74.1% |
| 5 y5 years | +97.9% | +131.8% |
LLY Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +54.7% | -6.7% | +74.1% |
| 5 y | 5 years | at high | +99.9% | -6.7% | +131.8% |
| alltime | all time | at high | +546.5% | -6.7% | +634.0% |
Eli Lilly And Company Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $10.29 B(-6.6%) |
| June 2024 | - | $11.03 B(+39.8%) |
| Mar 2024 | - | $7.89 B(-13.3%) |
| Dec 2023 | $9.09 B(+31.8%) | $9.09 B(+11.3%) |
| Sept 2023 | - | $8.17 B(+8.7%) |
| June 2023 | - | $7.52 B(-0.1%) |
| Mar 2023 | - | $7.53 B(+9.1%) |
| Dec 2022 | $6.90 B(+3.3%) | $6.90 B(+2.7%) |
| Sept 2022 | - | $6.72 B(+5.5%) |
| June 2022 | - | $6.36 B(+0.7%) |
| Mar 2022 | - | $6.32 B(-5.2%) |
| Dec 2021 | $6.67 B(+13.6%) | $6.67 B(+12.8%) |
| Sept 2021 | - | $5.91 B(+1.5%) |
| June 2021 | - | $5.83 B(+4.2%) |
| Mar 2021 | - | $5.59 B(-4.8%) |
| Dec 2020 | $5.88 B(+29.2%) | $5.88 B(+20.2%) |
| Sept 2020 | - | $4.89 B(+1.2%) |
| June 2020 | - | $4.83 B(-5.4%) |
| Mar 2020 | - | $5.11 B(+12.3%) |
| Dec 2019 | $4.55 B(-1.0%) | $4.55 B(+2.4%) |
| Sept 2019 | - | $4.44 B(-3.7%) |
| June 2019 | - | $4.61 B(+9.8%) |
| Mar 2019 | - | $4.20 B(-8.6%) |
| Dec 2018 | $4.59 B(+1.0%) | $4.59 B(-5.5%) |
| Sept 2018 | - | $4.86 B(+0.8%) |
| June 2018 | - | $4.82 B(+7.3%) |
| Mar 2018 | - | $4.50 B(-1.1%) |
| Dec 2017 | $4.55 B(+12.8%) | $4.55 B(+3.3%) |
| Sept 2017 | - | $4.40 B(+1.2%) |
| June 2017 | - | $4.35 B(+8.3%) |
| Mar 2017 | - | $4.02 B(-0.3%) |
| Dec 2016 | $4.03 B(+14.7%) | $4.03 B(+4.7%) |
| Sept 2016 | - | $3.85 B(-2.5%) |
| June 2016 | - | $3.95 B(+9.0%) |
| Mar 2016 | - | $3.62 B(+3.1%) |
| Dec 2015 | $3.51 B(+8.6%) | $3.51 B(+3.3%) |
| Sept 2015 | - | $3.40 B(+1.6%) |
| June 2015 | - | $3.35 B(+6.6%) |
| Mar 2015 | - | $3.14 B(-2.8%) |
| Dec 2014 | $3.23 B(-5.8%) | $3.23 B(+5.9%) |
| Sept 2014 | - | $3.05 B(-4.2%) |
| June 2014 | - | $3.19 B(+6.2%) |
| Mar 2014 | - | $3.00 B(-12.6%) |
| Dec 2013 | $3.43 B(+2.9%) | $3.43 B(-0.3%) |
| Sept 2013 | - | $3.44 B(-3.7%) |
| June 2013 | - | $3.58 B(+4.1%) |
| Mar 2013 | - | $3.44 B(+3.1%) |
| Dec 2012 | $3.34 B | $3.34 B(+2.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2012 | - | $3.27 B(+2.7%) |
| June 2012 | - | $3.18 B(-6.5%) |
| Mar 2012 | - | $3.40 B(-5.4%) |
| Dec 2011 | $3.60 B(+3.0%) | $3.60 B(+1.8%) |
| Sept 2011 | - | $3.53 B(-7.8%) |
| June 2011 | - | $3.83 B(+3.8%) |
| Mar 2011 | - | $3.69 B(+5.7%) |
| Dec 2010 | $3.49 B(+4.5%) | $3.49 B(+14.0%) |
| June 2010 | - | $3.07 B(-4.0%) |
| Mar 2010 | - | $3.19 B(-4.5%) |
| Dec 2009 | $3.34 B(+20.3%) | $3.34 B(+10.8%) |
| Sept 2009 | - | $3.02 B(+6.2%) |
| June 2009 | - | $2.84 B(+6.2%) |
| Mar 2009 | - | $2.68 B(-3.7%) |
| Dec 2008 | $2.78 B(+3.9%) | $2.78 B(+2.8%) |
| Sept 2008 | - | $2.70 B(-1.4%) |
| June 2008 | - | $2.74 B(+2.9%) |
| Mar 2008 | - | $2.66 B(-0.5%) |
| Dec 2007 | $2.67 B(+16.3%) | $2.67 B(+6.3%) |
| Sept 2007 | - | $2.52 B(+4.2%) |
| June 2007 | - | $2.41 B(+7.1%) |
| Mar 2007 | - | $2.25 B(-1.9%) |
| Dec 2006 | $2.30 B(-0.6%) | $2.30 B(+10.6%) |
| Sept 2006 | - | $2.08 B(-1.1%) |
| June 2006 | - | $2.10 B(-0.6%) |
| Mar 2006 | - | $2.11 B(-8.6%) |
| Dec 2005 | $2.31 B(+12.4%) | $2.31 B(+12.4%) |
| Sept 2005 | - | $2.06 B(-1.3%) |
| June 2005 | - | $2.09 B(-1.3%) |
| Mar 2005 | - | $2.11 B(+2.6%) |
| Dec 2004 | $2.06 B(+10.4%) | $2.06 B(+7.6%) |
| Sept 2004 | - | $1.91 B(-3.1%) |
| June 2004 | - | $1.97 B(+3.2%) |
| Mar 2004 | - | $1.91 B(+2.5%) |
| Dec 2003 | $1.86 B(+11.7%) | $1.86 B(+11.9%) |
| Sept 2003 | - | $1.67 B(-1.1%) |
| June 2003 | - | $1.68 B(+1.7%) |
| Mar 2003 | - | $1.66 B(-0.9%) |
| Dec 2002 | $1.67 B(+18.8%) | $1.67 B(+9.5%) |
| Sept 2002 | - | $1.53 B(-7.8%) |
| June 2002 | - | $1.66 B(+10.4%) |
| Mar 2002 | - | $1.50 B(+6.6%) |
| Dec 2001 | $1.41 B(-28.5%) | $1.41 B(+0.3%) |
| Sept 2001 | - | $1.40 B(-7.8%) |
| June 2001 | - | $1.52 B(+3.4%) |
| Mar 2001 | - | $1.47 B(-25.2%) |
| Dec 2000 | $1.97 B(+6.7%) | $1.97 B(+6.7%) |
| Dec 1999 | $1.84 B(+6.1%) | $1.84 B(+6.1%) |
| Dec 1996 | $1.74 B | $1.74 B |
FAQ
- What is Eli Lilly and Company annual accounts receivable?
- What is the all time high annual accounts receivable for Eli Lilly and Company?
- What is Eli Lilly and Company annual accounts receivable year-on-year change?
- What is Eli Lilly and Company quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Eli Lilly and Company?
- What is Eli Lilly and Company quarterly accounts receivable year-on-year change?
What is Eli Lilly and Company annual accounts receivable?
The current annual accounts receivable of LLY is $9.09 B
What is the all time high annual accounts receivable for Eli Lilly and Company?
Eli Lilly and Company all-time high annual accounts receivable is $9.09 B
What is Eli Lilly and Company annual accounts receivable year-on-year change?
Over the past year, LLY annual accounts receivable has changed by +$2.19 B (+31.82%)
What is Eli Lilly and Company quarterly accounts receivable?
The current quarterly accounts receivable of LLY is $10.29 B
What is the all time high quarterly accounts receivable for Eli Lilly and Company?
Eli Lilly and Company all-time high quarterly accounts receivable is $11.03 B
What is Eli Lilly and Company quarterly accounts receivable year-on-year change?
Over the past year, LLY quarterly accounts receivable has changed by +$2.13 B (+26.05%)